Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
June 2013
in “
Expert Review of Anticancer Therapy
”
TLDR Afatinib often causes skin problems that need proactive management.
Afatinib, an oral ErbB family blocker, was associated with frequent dermatologic adverse events (AEs) in patients, similar to other EGFR inhibitors. These AEs included papulopustular rash, pruritus, xerosis, paronychia, and alopecia, which significantly impacted patient well-being, adherence, and clinical outcomes. Effective management of these AEs required patient education and proactive treatment interventions. The article summarized data from clinical trials on afatinib's dermatologic AEs and provided strategies for managing them.
